Trial Profile
A Randomized Phase III Study of 5-Fluorouracil-based Regimen With or Without Oxaliplatin as 2nd Line Treatment of Advanced or Metastatic Pancreatic Cancer in Patients Who Have Previously Received Gemcitabine-based Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2017
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PANCREOX
- Sponsors Sanofi
- 06 Jun 2017 Results of pooled analysis of three studies including this study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 12 Sep 2016 Results published in the Journal of Clinical Oncology.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.